Tax

Foreign Tax (Deferred)

Vertex Pharmaceuticals Foreign Tax (Deferred) remained flat by 0.0% to $9.58M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 72.4%, from $34.65M to $9.58M. Over 2 years (FY 2023 to FY 2025), Foreign Tax (Deferred) shows a downward trend with a -16.8% CAGR.

Analysis

StatementIncome Statement
SectionTax
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

Indicates potential future tax impacts arising from international operations and global tax planning.

Detailed definition

The portion of the income tax provision that represents future tax liabilities or assets resulting from temporary differ...

Peer comparison

Standard accounting metric for multinational corporations.

Metric ID: is_msft_deferred_foreign_tax_expense

Historical Data

3 years
 FY'23FY'24FY'25
Value$55.30M$138.60M$38.30M
YoY Change—+150.6%-72.4%
Range$38.30M – $138.60M
CAGR-16.8%
Avg YoY Growth+39.1%
Median YoY Growth+39.1%

Frequently Asked Questions

What is Vertex Pharmaceuticals's foreign tax (deferred)?
Vertex Pharmaceuticals (VRTX) reported foreign tax (deferred) of $9.58M in Q4 2025.
How has Vertex Pharmaceuticals's foreign tax (deferred) changed year-over-year?
Vertex Pharmaceuticals's foreign tax (deferred) decreased by 72.4% year-over-year, from $34.65M to $9.58M.
What is the long-term trend for Vertex Pharmaceuticals's foreign tax (deferred)?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign tax (deferred) has grown at a -16.8% compound annual growth rate (CAGR), from $55.30M to $38.30M.
What does foreign tax (deferred) mean?
The portion of foreign income tax expense that is deferred to future periods due to timing differences.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.